Research News
National Comprehensive Cancer Network Updates Guidelines
(March 26, 2019) The NCCN, or the National Comprehensive Cancer Network, recently updated its clinical guidelines for the treatment of ovarian cancers…
OCRA Funded Study Aims to Increase Efficacy of PARP Inhibitors
(March 20, 2019) The Ovarian Cancer Dream Team, funded in part by OCRA, recently completed a Phase 1b Trial, which combined a PARP inhibitor with an HRR (homologous recombination repair) pathway inhibitor, such as PI3K, in order to increase the…
Action Alert: Tell Congress to Increase OCRP Funding
(March 19, 2019) Congress is considering a $15 million increase for OCRP funding. Urge YOUR Representative to sign the letter to help push this funding through…
Lymphadenectomy in Ovarian Cancer Patients Can Be Unnecessary
(March 18, 2019) Before the most recent study on the usage of lymphadenectomy, published earlier this month in the New England Journal of Medicine, it was thought that surgically removing clinically negative lymph nodes had a positive effect on the…
OCRA-Funded Research Indicates that Stem-Like Cells May Be Key to Preventing Recurrence
(March 15, 2019) Cell Reports recently published a study about a drug that, given in combination with chemotherapy, could greatly increase survival rates of ovarian cancer patients…
New Therapeutic Approaches for Mucinous Ovarian Cancer
(February 13, 2019) Data from a study conducted by researchers at MD Anderson and Johns Hopkins suggest that an adjuvant gastrointestinal (GI)-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous…
Drugs to Treat Hypertension May Enhance Ovarian Cancer Drugs
(January 23, 2019) Researchers at Massachusetts General Hospital recently found a correlation between a class of drug used to treat hypertension and longer survival rates in ovarian cancer patients when used with paclitaxel, a drug used to treat…
OCRA Awards $5.25 Million in Scientific Research Grants for 2019
(January 10, 2019) We’re pleased to announce OCRA’s newest research grants of $5.25 million to 23 top scientists at 14 top medical centers…
OCRA Funded Research Delves Deeper into How PARPi Work
(December 21, 2018) This month, researchers in Boston published their findings on how PARP inhibitors (PARPi) cause a chain reaction of responses from the tumor and its environment…
FDA Approves Olaparib for Frontline Maintenance Treatment in Ovarian Cancer
(December 20, 2018) Earlier this year a phase III clinical trial, known as SOLO-1, showed that frontline olaparib (Lynparza) can reduce the risk of disease progression or death by up to 70% in women with BRCA 1 or 2 positive, advanced stage…
Neoadjuvant Chemotherapy Recommended for Stage IV Tubo-Ovarian Cancer
(December 7, 2018) A study published last month analyzed two clinical trials that sought to determine the best first step for advanced tubo-ovarian cancers, neoadjuvant chemotherapy or debulking surgery…
Simple Cysts Found by Ultrasound Don’t Require Action
(November 16, 2018) JAMA Internal Medicine recently published an eleven year study of over 72,000 women that found having a simple ovarian cyst does not increase one’s risk of ovarian cancer…